Aerie Pharmaceuticals, Inc. (AERI)
| Previous close | 12.41 |
| Open | 12.70 |
| Bid | 12.49 x 800 |
| Ask | 12.55 x 900 |
| Day's range | 12.44 - 12.63 |
| 52-week range | 9.01 - 26.26 |
| Volume | 27,879 |
| Avg. volume | 728,723 |
| Market cap | 583.312M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.19 |
| Earnings date | 05 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.17 |
- Zacks
Bausch (BHC) Begins Second Phase III Study on NOV03 for DED
Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.
- Zacks
Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU
Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.
- Business Wire
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The recommended indication is the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.
